Symmetry Partners’s Charles River Laboratories CRL Stock Holding History

Symmetry Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,515	Closed	-$324K	–	550
2022 Q2	$324K	Sell	1,515 -182	-11%	-$44.5K	0.02%	441
2022 Q1	$482K	Hold	1,697	–	–	0.03%	374
2021 Q4	$639K	Sell	1,697 -306	-15%	-$119K	0.04%	322
2021 Q3	$804K	Hold	2,003	–	–	0.05%	274
2021 Q2	$741K	Hold	2,003	–	–	0.05%	302
2021 Q1	$581K	Hold	2,003	–	–	0.04%	345
2020 Q4	$500K	Buy	2,003 +446	+29%	+$106K	0.04%	372
2020 Q3	$353K	Buy	+1,557	New	+$323K	0.03%	434
2019 Q3	–	Sell	-2,102	Closed	-$298K	–	345
2019 Q2	$298K	Buy	2,102 +745	+55%	+$101K	0.06%	251
2019 Q1	$197K	Buy	1,357 +825	+155%	+$108K	0.03%	310
2018 Q4	$60K	Buy	+532	New	+$66.6K	0.02%	354

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Symmetry Partners's CRL Position: Q3 2022 in Review

Symmetry Partners sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 1,515 shares — an estimated $324K sold.

Symmetry Partners first reported a position in CRL in Q4 2018 and held it in 11 quarters. The position peaked at $804K in Q3 2021. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

Symmetry Partners reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
Symmetry Partners sold 1,515 Charles River Laboratories shares in Q3 2022, an estimated $324K.
Symmetry Partners first reported a position in Charles River Laboratories in Q4 2018 and held it in 11 quarters.
Symmetry Partners's Charles River Laboratories position peaked at $804K in Q3 2021.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Symmetry Partners's 13F filing for Q3 2022, filed 3 Oct 2022.